From the ∗Centre Hospitalier Universitaire de Montpellier, Hôpital Lapeyronie, Pharmacie, Département de Pharmacie Clinique Dispensation et Economie de Santé
†Université de Montpellier, Laboratoire de Pharmacie Clinique, UFR des Sciences Pharmaceutiques et Biologiques, Montpellier
‡Aix-Marseille Université, EA 3279 – Centre d’Études et de Recherche sur les Services de Santé et la Qualité de Vie, Faculté de Médecine Timone, Marseille
§Centre Hospitalier Universitaire de Montpellier, Hôpital Lapeyronie, Département de Chirurgie Orthopédique du Membre Inferieur et de Traumatologie
∥Department of Epidemiology, Biostatistics and Medical Information, Montpellier University Hospital
¶PhyMedExp, Université de Montpellier, INSERM, CNRS, CHU de Montpellier, France.
Correspondence: Pierre Renaudin, PharmD, 371 Av. du Doyen Gaston Giraud, 34090 Montpellier (e-mail: [email protected]).
All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; and no other relationships or activities that could appear to have influenced the submitted work.
What is already known about this subject: Pharmacist-led medication review have a positive effect on number of medication errors (ME), drug-related readmissions, and all-cause emergency department visits after hospital discharge, which should result in cost savings and cost avoidance.
The median cost-benefit ratio for clinical pharmacy services in hospitals was estimated between 3:1 and 7:1, indicating a positive return on investment.
Few studies have focused on the benefits and cost avoidance of a clinical pharmacist in a surgical department or did not take into account the probability of occurrence of ME or studied the organizational impact of pharmacist intervention.
What this study adds: Taking into account the probability of ME occurrence, the cost-benefit ratio is lower.
Furthermore, this study sheds light on the organizational effect of the pharmacist integrated into a care unit.
Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.journalpatientsafety.com).
